Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155401 | 0.77 | L3MBTL1 (0.42) | L3MBTL1NUDT1 | |
| SCHEMBL13693180 | 0.76 | L3MBTL1 (0.38) | L3MBTL1NUDT1 | |
| SCHEMBL104697 | 0.72 | L3MBTL1 (0.35) | L3MBTL1NUDT1 | |
| SCHEMBL103804 | 0.72 | NUDT1 (0.46) | L3MBTL1NUDT1 | |
| SCHEMBL8241472 | 0.70 | TTK (0.33) | — | |
| SCHEMBL19616357 | 0.70 | L3MBTL1 (0.33) | L3MBTL1NUDT1 | |
| SCHEMBL9938832 | 0.70 | KDM4E (0.50) | — | |
| SCHEMBL19629179 | 0.69 | L3MBTL1 (0.33) | L3MBTL1NUDT1 | |
| SCHEMBL14537018 | 0.68 | HRH3 (0.36) | L3MBTL1 | |
| SCHEMBL14507462 | 0.68 | CXCR4 (0.32) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | L3MBTL1 3942/4885NUDT1 1845/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | L3MBTL1 2624/4885NUDT1 2800/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | L3MBTL1 985/4885NUDT1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.